Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomasTanios Bekaii-Saab, Joseph Markowitz, Nichole Prescott, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 StudyJonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris, Herbert I Hurwitz, E Claire Dees, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 StudyRahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2005
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesNeil L Spector, Wenle Xia, Howard Burris, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2019
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164Dung T Le, Tae Won Kim, Eric Van Cutsem, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid TumorsDaniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.Clinical Lung Cancer|March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA StudyAnna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.Pageof 5